Navigation Links
Shire plc - Statement re: Media Speculation
Date:7/11/2014

DUBLIN, July 11, 2014 /PRNewswire/ --


Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. 

Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon.  Shire confirms it has held a meeting with representatives of AbbVie.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

A further update will be made when appropriate.  Shareholders are strongly advised to take no action in relation to AbbVie's proposal.  There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

A copy of this announcement will be available at http://www.shire.com.  The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Notes to editors 

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

http://www.shire.com

 

CONTACTS 

Shire 

Stephanie Fagan

+1-201-572-9581

FTI Consulting (Media Adviser to the Company) 

Andrew Lorenz (London)

+44-77-7564-1807

Ben Atwell (London)

+44-20-3727-1000

David B. Roady (New York)

+1-212-850-5600

Robert Stanislaro (New York)

+1-212-850-5600



'/>"/>
SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Launches Online Educational Resource Center for US Patients with Ulcerative Colitis
2. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. Shire to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
5. Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
6. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. Shire Reaches Agreement in Principle With U.S. Government
9. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
10. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
11. Shire Changes its NASDAQ Ticker Symbol to SHPG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
Breaking Biology Technology:
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):